🟢 Oscar Health Inc rallies 5.9% after Barclays upgrades to 'Overweight', boosts price target

Oscar Health Inc is trading 5.9% higher at $28.82 after a bullish analyst note from Barclays provided a fresh catalyst for the stock.

• Barclays upgraded OSCR to Overweight from Equal Weight and raised its price target to $35 from $30, citing significant growth potential in the Affordable Care Act (ACA) market.
• The analyst noted that as Oscar implements repricing strategies, its profit margins are expected to improve, leading to a potential re-rating of the stock.
• The upgrade builds on recent positive momentum after management reaffirmed its full-year 2026 guidance at the Goldman Sachs healthcare conference on June 8, citing favorable medical cost trends and a strong start to the year.